Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Revista alergia México
On-line version ISSN 2448-9190
Abstract
ESTRADA-GARCIA, Carlos David et al. Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing. Rev. alerg. Méx. [online]. 2022, vol.69, n.2, pp.89-92. Epub Feb 17, 2023. ISSN 2448-9190. https://doi.org/10.29262/ram.v69i2.1088.
Background:
The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.
Case report:
30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.
Conclusion:
An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
Keywords : Allergy; Anaphylaxis; Pfizer-BioNTech®; Skin testing; Polyethylene glycol.
